First patient enrolled In Isofol Medical the first test with Modufolin (R) for treatment of rectal cancer, neoadjuvant

Isofol medical AB has today announced that the company has the first patient enrolled in the exploratory phase I/II trial, LARS2, for the treatment of rectal cancer. A total of 43 to 58 patients receive Isofol the novel folate-based drug Modufolin ® in combination with the anti-cancer drug Alimta ®.

"This is an important milestone in Isofol the development since the process of the first human trial LARS2 with our new folate-based drug Modufolin is ®. We have great expectations as pre-clinical data Modufolin ® an elevated anti-tumor effect suggesting and reduced side effects of Alimta ® when administered in combination with Modufolin ®. We also hope that that the treated patients the benefit of pre-operative treatment experiences, "says Anders Rabbe, CEO of Isofol Medical.

The LARS2-process is a single-center, open-label, extensive feasibility study of Alimta ® (500 mg/m2) with Modufolin ® (50 to 100, or 10 mg/m2) in 43 to 58 chemotherapy-naive patients with newly diagnosed operable rectal cancer. The study is carried out in cooperation with the principal investigator Prof. Bengt Gustavsson and the Sahlgrenska University Hospital in Gothenburg, Sweden.

About Modufolin ®

Modufolin ® (6R-5, 10-methylenetetrahydrofolate) is a novel folate-based drug developed to increase the effectiveness and the side effects of antimetabolites used in the treatment of cancer. Modufolin ® is the main active metabolite of the used folate-based drug Leucovorin. Modufolin ® stabilizes the binding of certain antimetabolites to the target-enzyme Thymidylate Synthase (TS) and, unlike Leucovorin, requires no enzymatic metabolic activation, which allows for a better therapeutic effect.

About Alimta ®

Alimta ® (Eli Lilly and co.) is a folate analog metabolic inhibitor indicated for locally advanced or metastatic nonsquamous Non-Small Cell Lung cancer and mesothelioma.

Source:
Isofol Medical

Drug-information on Alimta.